Currently, IFN-α, primarily the IFN-α2a and IFN-α2b subtypes, remains a valuable treatment option for a select cohort of chronic hepatitis B patients, which is typically characterized by a finite treatment duration and the potential to induce a sustained functional cure [5], defined as sustained undetectable HBsAg and HBV DNA with or without the development of anti-HBs after a finite course of treatment, and potential long-term benefits in reducing hepatocellular carcinoma incidence [6]. The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.